 | • レポートコード：MRC2Q12-19318 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、PD-1/PDL-1阻害剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 PD-1/PDL-1阻害剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 PD-1/PDL-1阻害剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 PD-1/PDL-1阻害剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのPD-1/PDL-1阻害剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のPD-1/PDL-1阻害剤の売上および2028年までの予測に焦点を当てています。 PD-1/PDL-1阻害剤のグローバル主要企業には、GlaxoSmithKline plc、Bristol-Myers Squibb Company、Arcus Biosciences, Inc.、Agenus Inc、F. Hoffmann-La Roche Ltd、Astra Zeneca PLC、Beigene Ltd、Incyte Corporation、Biocad、CStone Pharmaceuticals、Shanghai Junshi Bioscience Co. Ltd、Shanghai Henlius Biotech, Inc.、Jiangsu HengRui Medicine Co., Ltd.、Lee's Pharmaceutical Limitedなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 PD-1/PDL-1阻害剤市場は、タイプとアプリケーションによって区分されます。世界のPD-1/PDL-1阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 ペンブロリズマブ、ニボルマブ、アテゾリズマブ、デュルバルマブ、アベルマブ 【アプリケーション別セグメント】 胃がん、肝臓がん、腎臓がん、膀胱がん、子宮頸がん、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - PD-1/PDL-1阻害剤製品概要 - タイプ別市場（ペンブロリズマブ、ニボルマブ、アテゾリズマブ、デュルバルマブ、アベルマブ） - アプリケーション別市場（胃がん、肝臓がん、腎臓がん、膀胱がん、子宮頸がん、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のPD-1/PDL-1阻害剤販売量予測2017-2028 - 世界のPD-1/PDL-1阻害剤売上予測2017-2028 - PD-1/PDL-1阻害剤の地域別販売量 - PD-1/PDL-1阻害剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別PD-1/PDL-1阻害剤販売量 - 主要メーカー別PD-1/PDL-1阻害剤売上 - 主要メーカー別PD-1/PDL-1阻害剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（ペンブロリズマブ、ニボルマブ、アテゾリズマブ、デュルバルマブ、アベルマブ） - PD-1/PDL-1阻害剤のタイプ別販売量 - PD-1/PDL-1阻害剤のタイプ別売上 - PD-1/PDL-1阻害剤のタイプ別価格 ・アプリケーション別市場規模（胃がん、肝臓がん、腎臓がん、膀胱がん、子宮頸がん、その他） - PD-1/PDL-1阻害剤のアプリケーション別販売量 - PD-1/PDL-1阻害剤のアプリケーション別売上 - PD-1/PDL-1阻害剤のアプリケーション別価格 ・北米市場 - 北米のPD-1/PDL-1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PDL-1阻害剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのPD-1/PDL-1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PDL-1阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のPD-1/PDL-1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PDL-1阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のPD-1/PDL-1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PDL-1阻害剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのPD-1/PDL-1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PDL-1阻害剤市場規模（トルコ、サウジアラビア） ・企業情報 GlaxoSmithKline plc、Bristol-Myers Squibb Company、Arcus Biosciences, Inc.、Agenus Inc、F. Hoffmann-La Roche Ltd、Astra Zeneca PLC、Beigene Ltd、Incyte Corporation、Biocad、CStone Pharmaceuticals、Shanghai Junshi Bioscience Co. Ltd、Shanghai Henlius Biotech, Inc.、Jiangsu HengRui Medicine Co., Ltd.、Lee's Pharmaceutical Limited ・産業チェーン及び販売チャネル分析 - PD-1/PDL-1阻害剤の産業チェーン分析 - PD-1/PDL-1阻害剤の原材料 - PD-1/PDL-1阻害剤の生産プロセス - PD-1/PDL-1阻害剤の販売及びマーケティング - PD-1/PDL-1阻害剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - PD-1/PDL-1阻害剤の産業動向 - PD-1/PDL-1阻害剤のマーケットドライバー - PD-1/PDL-1阻害剤の課題 - PD-1/PDL-1阻害剤の阻害要因 ・主な調査結果 |
PD-1 inhibitors, including PD-1 antibodies and PD-L1 antibodies, are a new class of immunotherapy drugs. The main mechanism of action is to block the interaction between PD-1 and PD-L1, because the interaction of these two proteins will help tumors escape the pursuit of the immune system, a typical “helping evil”. PD-1/PD-L1 antibodies, by blocking this “sinful connection”, promote the patient’s own immune system to kill tumors.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
PD-1/PD-L1 inhibitors are the research hotspot of tumor immunotherapy in recent years. Since September 2014, they have been officially approved by the US FDA for: malignant melanoma, non-small cell lung cancer, liver cancer, gastric cancer, kidney cancer , bladder cancer, head and neck tumors, Hodgkin lymphoma, cervical cancer, Merkel cell carcinoma, and all solid tumors with microsatellite high instability (MSI-H). Phase III clinical trials of PD-1 inhibitors in small cell lung cancer, esophageal cancer, and triple-negative breast cancer have been successful, and the corresponding indications will be officially approved soon. In addition, it has been shown in various other solid tumors such as colorectal cancer, nose and throat cancer, ovarian cancer, prostate cancer, endometrial cancer, glioma, neuroendocrine tumor, malignant mesothelioma, non-Hodgkin’s lymphoma, etc. Initial, encouraging results.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the PD-1 and PDL-1 Inhibitors manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional PD-1 and PDL-1 Inhibitors market. Further, it explains the major drivers and regional dynamics of the global PD-1 and PDL-1 Inhibitors market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
GlaxoSmithKline plc
Bristol-Myers Squibb Company
Arcus Biosciences, Inc.
Agenus Inc
F. Hoffmann-La Roche Ltd
Astra Zeneca PLC
Beigene Ltd
Incyte Corporation
Biocad
CStone Pharmaceuticals
Shanghai Junshi Bioscience Co. Ltd
Shanghai Henlius Biotech, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Lee’s Pharmaceutical Limited
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
PD-1 and PDL-1 Inhibitors Segment by Type
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
PD-1 and PDL-1 Inhibitors Segment by Application
Stomach Cancer
Liver Cancer
Kidney Ccancer
Bladder Cancer
Cervical Cancer
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the PD-1 and PDL-1 Inhibitors market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for PD-1 and PDL-1 Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of PD-1 and PDL-1 Inhibitors, also provides the sales of main regions and countries. Highlights of the upcoming market potential for PD-1 and PDL-1 Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PDL-1 Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global PD-1 and PDL-1 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for PD-1 and PDL-1 Inhibitors sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc., Agenus Inc, F. Hoffmann-La Roche Ltd, Astra Zeneca PLC, Beigene Ltd, Incyte Corporation and Biocad, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of PD-1 and PDL-1 Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of PD-1 and PDL-1 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PDL-1 Inhibitors sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 PD-1 and PDL-1 Inhibitors Product Introduction
1.2 Market by Type
1.2.1 Global PD-1 and PDL-1 Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Atezolizumab
1.2.5 Durvalumab
1.2.6 Avelumab
1.3 Market by Application
1.3.1 Global PD-1 and PDL-1 Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Stomach Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Ccancer
1.3.5 Bladder Cancer
1.3.6 Cervical Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global PD-1 and PDL-1 Inhibitors Sales Estimates and Forecasts 2017-2028
2.2 Global PD-1 and PDL-1 Inhibitors Revenue Estimates and Forecasts 2017-2028
2.3 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global PD-1 and PDL-1 Inhibitors Sales by Region
2.4.1 Global PD-1 and PDL-1 Inhibitors Sales by Region (2017-2022)
2.4.2 Global Sales PD-1 and PDL-1 Inhibitors by Region (2023-2028)
2.5 Global PD-1 and PDL-1 Inhibitors Revenue by Region
2.5.1 Global PD-1 and PDL-1 Inhibitors Revenue by Region (2017-2022)
2.5.2 Global PD-1 and PDL-1 Inhibitors Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global PD-1 and PDL-1 Inhibitors Sales by Manufacturers
3.1.1 Global Top PD-1 and PDL-1 Inhibitors Manufacturers by Sales (2017-2022)
3.1.2 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PD-1 and PDL-1 Inhibitors in 2021
3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturers
3.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturers (2017-2022)
3.2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PDL-1 Inhibitors Revenue in 2021
3.3 Global PD-1 and PDL-1 Inhibitors Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global PD-1 and PDL-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global PD-1 and PDL-1 Inhibitors Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global PD-1 and PDL-1 Inhibitors Sales by Type
4.1.1 Global PD-1 and PDL-1 Inhibitors Historical Sales by Type (2017-2022)
4.1.2 Global PD-1 and PDL-1 Inhibitors Forecasted Sales by Type (2023-2028)
4.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2017-2028)
4.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type
4.2.1 Global PD-1 and PDL-1 Inhibitors Historical Revenue by Type (2017-2022)
4.2.2 Global PD-1 and PDL-1 Inhibitors Forecasted Revenue by Type (2023-2028)
4.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2017-2028)
4.3 Global PD-1 and PDL-1 Inhibitors Price by Type
4.3.1 Global PD-1 and PDL-1 Inhibitors Price by Type (2017-2022)
4.3.2 Global PD-1 and PDL-1 Inhibitors Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global PD-1 and PDL-1 Inhibitors Sales by Application
5.1.1 Global PD-1 and PDL-1 Inhibitors Historical Sales by Application (2017-2022)
5.1.2 Global PD-1 and PDL-1 Inhibitors Forecasted Sales by Application (2023-2028)
5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2017-2028)
5.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application
5.2.1 Global PD-1 and PDL-1 Inhibitors Historical Revenue by Application (2017-2022)
5.2.2 Global PD-1 and PDL-1 Inhibitors Forecasted Revenue by Application (2023-2028)
5.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2017-2028)
5.3 Global PD-1 and PDL-1 Inhibitors Price by Application
5.3.1 Global PD-1 and PDL-1 Inhibitors Price by Application (2017-2022)
5.3.2 Global PD-1 and PDL-1 Inhibitors Price Forecast by Application (2023-2028)
6 North America
6.1 North America PD-1 and PDL-1 Inhibitors Market Size by Type
6.1.1 North America PD-1 and PDL-1 Inhibitors Sales by Type (2017-2028)
6.1.2 North America PD-1 and PDL-1 Inhibitors Revenue by Type (2017-2028)
6.2 North America PD-1 and PDL-1 Inhibitors Market Size by Application
6.2.1 North America PD-1 and PDL-1 Inhibitors Sales by Application (2017-2028)
6.2.2 North America PD-1 and PDL-1 Inhibitors Revenue by Application (2017-2028)
6.3 North America PD-1 and PDL-1 Inhibitors Market Size by Country
6.3.1 North America PD-1 and PDL-1 Inhibitors Sales by Country (2017-2028)
6.3.2 North America PD-1 and PDL-1 Inhibitors Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe PD-1 and PDL-1 Inhibitors Market Size by Type
7.1.1 Europe PD-1 and PDL-1 Inhibitors Sales by Type (2017-2028)
7.1.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Type (2017-2028)
7.2 Europe PD-1 and PDL-1 Inhibitors Market Size by Application
7.2.1 Europe PD-1 and PDL-1 Inhibitors Sales by Application (2017-2028)
7.2.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Application (2017-2028)
7.3 Europe PD-1 and PDL-1 Inhibitors Market Size by Country
7.3.1 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2017-2028)
7.3.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Type
8.1.1 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Type (2017-2028)
8.1.2 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Type (2017-2028)
8.2 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Application
8.2.1 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Application (2017-2028)
8.2.2 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Application (2017-2028)
8.3 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Region
8.3.1 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Region (2017-2028)
8.3.2 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America PD-1 and PDL-1 Inhibitors Market Size by Type
9.1.1 Latin America PD-1 and PDL-1 Inhibitors Sales by Type (2017-2028)
9.1.2 Latin America PD-1 and PDL-1 Inhibitors Revenue by Type (2017-2028)
9.2 Latin America PD-1 and PDL-1 Inhibitors Market Size by Application
9.2.1 Latin America PD-1 and PDL-1 Inhibitors Sales by Application (2017-2028)
9.2.2 Latin America PD-1 and PDL-1 Inhibitors Revenue by Application (2017-2028)
9.3 Latin America PD-1 and PDL-1 Inhibitors Market Size by Country
9.3.1 Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2017-2028)
9.3.2 Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Type
10.1.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Type (2017-2028)
10.1.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Type (2017-2028)
10.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Application
10.2.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Application (2017-2028)
10.2.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Application (2017-2028)
10.3 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Country
10.3.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Country (2017-2028)
10.3.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Corporation Information
11.1.2 GlaxoSmithKline plc Overview
11.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline plc Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Overview
11.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bristol-Myers Squibb Company Recent Developments
11.3 Arcus Biosciences, Inc.
11.3.1 Arcus Biosciences, Inc. Corporation Information
11.3.2 Arcus Biosciences, Inc. Overview
11.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Arcus Biosciences, Inc. Recent Developments
11.4 Agenus Inc
11.4.1 Agenus Inc Corporation Information
11.4.2 Agenus Inc Overview
11.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Agenus Inc Recent Developments
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Corporation Information
11.5.2 F. Hoffmann-La Roche Ltd Overview
11.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 F. Hoffmann-La Roche Ltd Recent Developments
11.6 Astra Zeneca PLC
11.6.1 Astra Zeneca PLC Corporation Information
11.6.2 Astra Zeneca PLC Overview
11.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Astra Zeneca PLC Recent Developments
11.7 Beigene Ltd
11.7.1 Beigene Ltd Corporation Information
11.7.2 Beigene Ltd Overview
11.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Beigene Ltd Recent Developments
11.8 Incyte Corporation
11.8.1 Incyte Corporation Corporation Information
11.8.2 Incyte Corporation Overview
11.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Incyte Corporation Recent Developments
11.9 Biocad
11.9.1 Biocad Corporation Information
11.9.2 Biocad Overview
11.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Biocad Recent Developments
11.10 CStone Pharmaceuticals
11.10.1 CStone Pharmaceuticals Corporation Information
11.10.2 CStone Pharmaceuticals Overview
11.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 CStone Pharmaceuticals Recent Developments
11.11 Shanghai Junshi Bioscience Co. Ltd
11.11.1 Shanghai Junshi Bioscience Co. Ltd Corporation Information
11.11.2 Shanghai Junshi Bioscience Co. Ltd Overview
11.11.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments
11.12 Shanghai Henlius Biotech, Inc.
11.12.1 Shanghai Henlius Biotech, Inc. Corporation Information
11.12.2 Shanghai Henlius Biotech, Inc. Overview
11.12.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
11.13 Jiangsu HengRui Medicine Co., Ltd.
11.13.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
11.13.2 Jiangsu HengRui Medicine Co., Ltd. Overview
11.13.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
11.14 Lee’s Pharmaceutical Limited
11.14.1 Lee’s Pharmaceutical Limited Corporation Information
11.14.2 Lee’s Pharmaceutical Limited Overview
11.14.3 Lee’s Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Lee’s Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Lee’s Pharmaceutical Limited Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 PD-1 and PDL-1 Inhibitors Industry Chain Analysis
12.2 PD-1 and PDL-1 Inhibitors Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PD-1 and PDL-1 Inhibitors Production Mode & Process
12.4 PD-1 and PDL-1 Inhibitors Sales and Marketing
12.4.1 PD-1 and PDL-1 Inhibitors Sales Channels
12.4.2 PD-1 and PDL-1 Inhibitors Distributors
12.5 PD-1 and PDL-1 Inhibitors Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 PD-1 and PDL-1 Inhibitors Industry Trends
13.2 PD-1 and PDL-1 Inhibitors Market Drivers
13.3 PD-1 and PDL-1 Inhibitors Market Challenges
13.4 PD-1 and PDL-1 Inhibitors Market Restraints
14 Key Findings in The Global PD-1 and PDL-1 Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer